Clinical features suggesting the presence of PVOD, number of evaluable cells, and Golde score.

<p>6-MWD: 6-minute walking distance. mPAP: mean pulmonary artery pressure. CI: cardiac index. PVR: pulmonary vascular resistance. WU: Wood units. PAWP: pulmonary artery wedge pressure. DLCO: diffusion capacity. PaO₂: partial pressure of oxygen in arterial blood.</p><p>Clinical features suggesting the presence of PVOD, number of evaluable cells, and Golde score.</p

Haemosiderin-laden macrophages are significantly (<i>P</i><0.05) more present in sputum from PVOD patients as compared to the others (IPAH, CTEPH and SAPH, respectively).

<p>Haemosiderin-laden macrophages are significantly (<i>P</i><0.05) more present in sputum from PVOD patients as compared to the others (IPAH, CTEPH and SAPH, respectively).</p

Histologic specimen from a patient suffering from PVOD who underwent lung transplantation.

<p>Intimal thickening and fibrous obstruction of septal veins and preseptal venules (asterixis) as well as features of pulmonary capillary hemangiomatosis with proliferation of dilated and congested capillaries as well as dilated lymphatic (left upper and right lower part of the figure; arrowhead). Alveoli with haemosiderin-laden macrophages of Golde score 3–4 (arrow) are clearly visible. Haemosiderin-negativ macrophages are difficult to be identified. Golde score from the tissue was 304, as compared to 252 in the sputum.</p

Clinical characteristics of the four patient groups.

<p>Clinical characteristics of the four patient groups.</p

Description of the Golde score calculation in sputum macrophages.

<p>Description of the Golde score calculation in sputum macrophages.</p

HDL regulates Sirt1 expression. A.

<p>Sirt1 protein expression in THP1 cells after incubation with HDL from healthy subjects or patients suffering from CAD and ACS, respectively. <b>B.</b> PON1 function, as measured by PON1 arylesterase activity, is significantly reduced in the CAD and ACS group.</p

Sirt1 expression is reduced in patients suffering from atherosclerotic disease. A.

<p>HDL levels are reduced in patients suffering from CAD or ACS as compared to the healthy controls. <b>B.</b> Flow cytometry analysis demonstrates the purity of isolated monocytes. <b>C.</b> Sirt1 mRNA expression in relation to 18S rRNA in peripheral blood monocytes isolated from healthy subjects, from patients with angiographically-confirmed CAD and patients presenting with an ACS. <b>D.</b> The expression of interleukin-6 (IL-6), a negatively regulated Sirt1-dependent marker, is increased in patients with impaired Sirt1-expression.</p

Clinical characteristics of the three patient groups.

*<p>0.05* CADnts with CAD and ACS,ACS group)erosclerosis looses its cardioprotectice properties.**</p>*<p>ACS vs CAD.</p>†<p>Healthy vs CAD.</p>‡<p>Healthy vs ACS.</p